Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.46 ▼ -0.04
(-2.67%)
MKT CAP: $264.4M • VOL: 1.45M
52W L $0 52W H $3
IPSC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $109.2M | $6.6M | $2.2M |
| YoY Revenue Growth % | +1556.8% | +194.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.3M | -$138.1M | -$146.5M |
| Operating Margin % | -15.8% | -80.0% | -80.0% |
| Net Income (GAAP) | -$9.6M | -$126.6M | -$136.7M |
| EBITDA (Normalized) | -$16.6M | -$138.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$103.9M | -$110.1M | -$88.3M |
| Capital Expenditures (CapEx) | $848.0K | $154.0K | — |
| Free Cash Flow (FCF) | -$104.7M | -$110.3M | -$88.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -14.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $61.9M | $58.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $158.9M | $161.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IPSC.